Lipidomic profiling reveals free fatty acid alterations in plasma from patients with atrial fibrillation

Youngae Jung¹,²☯, Youngjin Cho³☯, Nami Kim¹, Il-Young Oh³, Sang Won Kang², Eue-Keun Choi⁴*, Geum-Sook Hwang¹,⁵*

¹ Integrated Metabolomics Research Group, Western Seoul Center, Korea Basic Science Institute, Seoul, Republic of Korea, ² Department of Life Science, Ewha Womans University, Seoul, Republic of Korea, ³ Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁴ Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁵ Department of Chemistry & Nanoscience, Ewha Womans University, Seoul, Republic of Korea

☯ These authors contributed equally to this work.
* choiek17@snu.ac.kr (E-KC); gshwang@kbsi.re.kr (G-SH)

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence is increasing worldwide. One method used to restore sinus rhythm is direct current cardioversion (DCCV). Despite the high success rate of DCCV, AF typically recurs within the first 2 weeks. However, our understanding of the pathophysiology of AF recurrence, incidence, and progression are highly limited. Lipidomic profiling was applied to identify altered lipids in plasma from patients with AF using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry coupled with multivariate statistical analysis. Partial least-squares discriminant analysis revealed a clear separation between AF patients and healthy controls. The levels of several lipid species, including fatty acids and phospholipids, were different between AF patients and healthy controls, indicating that oxidative stress and inflammation are associated with the pathogenesis of AF. Similar patterns were also detected between recurrent and non-recurrent AF patients. These results suggest that the elevated saturated fatty acid and reduced polyunsaturated fatty acid levels in AF patients may be associated with enhanced inflammation and that free fatty acid levels may play a crucial role in the development and progression of AF.

Introduction

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. It is associated with a high risk of stroke, hospitalization, and reduced quality of life [1]. Although it can develop from a complex interaction between various factors, its pathophysiology has not yet been elucidated [2, 3]. Direct current cardioversion (DCCV) is a method used to restore sinus rhythm by electrical shock [4, 5]. Although the acute success rate of DCCV is greater than 90%, AF recurrence is common, particularly within the first 2 weeks, reaching 40% recurrence
in the first month, despite treatment with anti-arrhythmic agents [6]. A long duration of AF, a large left atrium (LA), old age, underlying comorbidities, and increased heart rate variability are related to AF recurrence after DCCV [7–9]. However, the predictive values of these clinical factors are relatively low. In addition, a better understanding of the pathophysiology of AF is essential for the discovery of new therapeutic targets. As our understanding of the mechanism of AF has improved considerably, many studies have indicated that oxidative stress and inflammation play an important role in the incidence, perpetuation, and recurrence of AF [1, 10–12].

Lipids play important roles as signaling molecules, energy sources, and structural components of biological membranes [13]. Accordingly, changes in lipids due to genetic or environmental changes can greatly influence cell function, the immune system, and inflammatory responses [14]. A lipidomics approach that identifies global changes in lipid metabolites has been effectively applied in various dysregulation-related diseases, such as obesity [13, 15] and coronary artery disease [14].

To date, only a limited number of metabolic profiling studies on AF have been conducted. These reports have described the aqueous metabolite profiles of atrial tissues from AF patients [16] or animal models [17] and serum samples from AF patients [18]. And lipid profiles including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides have been provided from patients with AF to present the association with incidence of AF [19, 20]. However, to the best of our knowledge, no detailed plasma lipidome as well as free fatty acid profiling have been reported in AF patients. In the present study, global lipid profiling was conducted to identify altered lipid metabolites in plasma from AF patients using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (Q-TOF MS). We also investigated the impact of lipid profiles in plasma on recurrence after successful DCCV to understand the pathophysiology of AF and to present preventive and therapeutic strategies for the occurrence and recurrence of AF.

Methods

Study population

Patients who underwent elective DCCV for persistent AF between August 2010 and June 2013 at Seoul National University Hospital were evaluated. This study was approved by the Institutional Review Board of Seoul National University Hospital. All patients provided informed written consent. Persistent AF was confirmed by a 12-lead electrocardiogram (ECG) and 24 h Holter monitoring. Patients who had significant mitral valvular disease, had a very large LA (>60 mm), underwent emergent cardioversion, those with end-stage renal disease, or declined to consent to the study were excluded. In total, 182 patients were eligible for this study, and 52 patients who underwent electrophysiological analysis due to suspicion of paroxysmal supraventricular tachycardia without any history of AF were prospectively enrolled as healthy controls. A total of 34 patients matched by age, sex, and body mass index (BMI) were analyzed to compare the metabolomic profiles between the AF and control groups. Metabolomics profiles were also compared between AF patients who maintained sinus rhythm and who experienced AF recurrence within 1 month after electrical cardioversion, also after matching by age, sex, BMI, and LA size.

Electrical cardioversion protocol

All patients received more than 4 weeks of adequate anticoagulation therapy (with a target International Normalized Ratio of 2.0–3.0) before elective DCCV. Before electrical DCVC,
anti-arrhythmic agents were prescribed in most patients according to guidelines described previously [21]. To exclude an intra-cardiac thrombus, transesophageal echocardiography was performed on the day of cardioversion. A light sedative was administered intravenously (midazolam, 0.05–0.2 mg/kg or etomidate, 0.1 mg/kg). A biphasic R-wave synchronized shock (ZOLL M series® ACLS Defibrillator, ZOLL Medical Corporation, Chelmsford, MA, USA) was applied via paddles on the right side of the upper sternum and the left side of the left nipple. The initial cardioversion energy was 100 J and was increased to 150 and 200 J. If AF was not terminated, self-adhesive skin electrodes (ZOLL Stat-padz®, ZOLL Medical Corporation) were applied in anterior–posterior position, using a 200 J energy shock. After successful cardioversion, all patients were monitored for at least 3–4 h before discharge. After discharge, all patients received anticoagulation therapy for more than 3 months without interruption.

Then, 1 month after successful cardioversion, patients visited the outpatient clinic for evaluation with the 12-lead ECG. AF recurrence was confirmed following 12-lead ECG and physical examination. The recurrent AF group was defined as those with documented AF on the 12-lead ECG, and the sinus rhythm group (non-recurrent AF group) was defined as those on sinus rhythm at the 1-month follow-up.

**Blood sampling**

Venipuncture was performed before electrical cardioversion in AF patients. Blood samples were extracted in the documented sinus rhythm prior to electrophysiological analysis in the control group. Anticoagulated whole blood samples were centrifuged at 2500rpm/700g (Heraeus Megafuge 40R, Thermo Fisher Scientific) for 15 minutes at 4˚C, and plasma sample aliquots were stored at -80˚C for the subsequent analysis.

**Lipid metabolite profiling using UPLC/Q-TOF MS**

Plasma samples (50 μL) were extracted using a 500 μL chloroform:methanol (2:1, v/v) solution and dried under nitrogen gas. Lipid extracts were reconstituted into a 250 μL isopropanol:acetonitrile:water (2:1:1, v/v/v) solution. Finally, 5 μL solution was injected into the UPLC/Q-TOF MS system.

Lipid metabolite profiling was performed using the Waters ACQUITY UPLC system (Waters, Milford, MA, USA) with a triple TOF 5600 Mass Spectrometer (SCIEX, Framingham, MA, USA). Separation was performed on an Acquity UPLC BEH C18 (2.1 × 100 mm) with 1.7 μm particles (Waters). Mobile phases A and B involved 10 mM ammonium acetate in an acetonitrile:water (4:6, v/v) solution and 10 mM ammonium acetate in an acetonitrile:isopropanol (1:9, v/v) solution, respectively. Samples were eluted at 0.35 mL/min for 19 min. The mass spectrometer was analyzed in the electrospray ionization positive and negative ion modes, and the mass range was set at m/z 100–1500. Accurate mass measurements for each peak were obtained with an automated calibrant delivery system (CDS) using 0.2 mL/min of positive and negative calibration solution (SCIEX) containing internal reference compounds.

Spectral data were analyzed with MarkerView software (SCIEX), which was used to identify peaks, perform the alignment, and generate peak tables of m/z and retention times. Lipid metabolites were identified using Lipid Maps (www.lipidmaps.org), the Human Metabolome Database (www.hmdb.ca), and Metlin (metlin.scrips.edu). Data were confirmed using standard samples (Avanti Polar Lipids, Alabaster, AL, USA and Sigma-Aldrich, St. Louis, MO, USA) based on retention times and MS/MS spectra.
RT-qPCR analysis

Additional plasma samples were collected from 6 healthy controls and 6 patients with AF to measure the mRNA cytokine. Total RNA was extracted from human plasma using a miRNeasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. RNA concentration and quality were immediately determined using a Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Human plasma RNA served as a template for synthesizing cDNA using the GoTaq® 1-Step RT-qPCR System according to the manufacturer’s instructions (Promega, Madison, WI, USA). Reactions were carried out using SYBR Green for 40 cycles of denaturation at 95˚C for 10 s, annealing at 60˚C for 30 s, and extension at 72˚C for 30 s using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). qPCR was performed using the following primers: IL-1β sense (5’-TGG GAT AAC GAG GCT TAT GTG-3’) and antisense (5’-ATG GAG ACC ACT TGT TGC-3’), tumor necrosis factor alpha (TNF-α) sense (5’-CTC CTA CCA GAC GAA GGT CAA C-3’) and antisense (5’-AGA CTC GCC AAA GTC GAG ATA G-3’), and β-actin sense (5’-CCA CGA AAC TAC CTT CAA CTC C-3’) and antisense (5’-GGA GCA ATG ATC TTG ATC TTC A-3’). The experiment was performed on three independent biological replicates. Gene expression was normalized to the mRNA expression level of β-actin (endogenous control). For control samples, fold changes were calculated using relative quantification.

Statistical analysis

Multivariate analyses were conducted using SIMCA-P+ software version 12.0 (Umetrics, Umeå, Sweden). Principle component analysis (PCA) was applied to determine the intrinsic variation in the data set, and partial least squares discriminant analysis (PLS-DA) was used as a classification method. Lipid metabolites with a variable importance in the projection (VIP) score > 1 were considered to be the metabolites responsible for the differences between healthy controls and AF patients.

SPSS 15.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. Mann–Whitney U, chi-square tests, and Fisher’s exact test were used to detect differences in the clinical characteristics and lipid metabolites between healthy controls and patients (p < 0.05). Spearman’s correlation coefficient was used to determine the relationships between clinical parameters and levels of free fatty acids (FFAs).

Results

Patient characteristics

Baseline clinical characteristics of age-, sex-, and BMI-matched AF patients and controls are shown in Table 1. There were no significant differences in the presence of comorbidities such as hypertension and diabetes mellitus, between the AF and control groups. The size of the LA measured by echocardiography was significantly larger in the AF group (AF vs. control: 47.6 ± 7.0 vs. 36.7 ± 5.9, p < 0.001). Anticoagulant and anti-arrhythmic agents were more frequently prescribed in patients with AF than healthy controls. The proportion of patients taking a statin or an anti-diabetic agent did not differ between groups.

Lipid profiling of AF patients

Total ion chromatograms of lipid extracts were obtained by UPLC/Q-TOF MS in positive and negative ion modes (S1 Fig). Phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM), and triglyceride (TG) were detected in the positive ion mode, and FFAs, phosphatidylinositol (PI), and phosphatic acid (PA) were detected in the negative ion mode.
Lipid species were identified by the accurate mass, isotope patterns, MS/MS fragmentation data, and relative retention time of the same species.

Multivariate pattern recognition methods were applied to identify lipidomic changes in patients with AF. Principle component analysis (PCA) score plots showed better separation in the negative ion mode between patients and healthy controls than in the positive ion mode (Fig 1A and 1B). The reproducibility of metabolite signals was confirmed by quality control samples injected repeatedly between samples in the PCA score plots. According to partial least squares discriminant analysis (PLS-DA), the two groups were clearly separated in both polarity modes (positive ion mode: R2X = 0.387, R2Y = 0.967, Q2 = 0.863; negative ion mode: R2X = 0.477, R2Y = 0.934, Q2 = 0.846) (Fig 1C and 1D).

Lipid metabolites with VIP scores > 1 in the PLS-DA and a p value < 0.05 were considered significant lipid species; a total of 33 lipids were identified (Table 2). The levels of all identified FFAs were lower in AF patients than in the controls. LysoPC, LysoPE, and PC levels were greater in AF patients than in controls when they had a relatively low degree of unsaturation; by contrast, these species were decreased in AF patients when they had a relatively high degree of unsaturation. Regarding the other lipid classes (i.e., PE, SM, TG, PA, and PI), only one lipid per class was significantly upregulated in AF patients relative to controls.

### Table 1. Clinical characteristics of healthy controls and patients with AF.

|                     | Healthy controls (n = 34) | AF patients (n = 34) | P value |
|---------------------|---------------------------|----------------------|---------|
| Age (years)         | 54.1 ± 8.67               | 56.2 ± 9.70          | 0.354   |
| Male/Female         | 13 / 21                   | 13 / 21              | 1.000   |
| BMI (kg/m²)         | 24.1 ± 3.59               | 24.6 ± 2.90          | 0.497   |
| Hypertension        | 8 (23.5)                  | 11 (32.4)            | 0.417   |
| Diabetes            | 4 (11.8)                  | 3 (8.8)              | 1.000   |
| Hypercholesterolemia| 4 (11.8)                  | 4 (11.8)             | 1.000   |
| Coronary artery disease | 0 (0.0)             | 0 (0.0)               | -       |
| Congestive heart failure | 0 (0.0)               | 0 (0.0)               | -       |
| Cerebrovascular accident | 0 (0.0)               | 0 (0.0)               | -       |
| LA size, mm         | 36.7 ± 5.9                | 47.6 ± 7.0           | <0.001  |
| LA volume, mL       | 36.4 ± 9.0                | 97.0 ± 32.7          | <0.001  |
| Medication          |                           |                      |         |
| Anticoagulant agent | 0 (0.0)                  | 33 (97.1)            | <0.001  |
| Antiplatelet agent  | 0 (0.0)                  | 1 (2.9)              | 1.000   |
| Anti-arrhythmic drug| 0 (0.0)                  | 33 (97.1)            | <0.001  |
| ACE inhibitor or ARB| 7 (20.6)                 | 12 (35.3)            | 0.177   |
| Beta-blocker        | 1 (2.9)                  | 3 (8.8)              | 0.614   |
| Calcium channel blocker | 4 (11.8)            | 4 (11.8)             | 1.000   |
| Statin              | 3 (8.8)                  | 4 (11.8)             | 1.000   |
| Anti-diabetic drugs | 2 (5.9)                  | 1 (2.9)              | 1.000   |

Data are presented as means ± standard deviations. P values were calculated using the Mann–Whitney U, chi-square tests, and Fisher’s exact test with significance set at \( p < 0.05 \). Abbreviations: AF, atrial fibrillation; BMI, body mass index; LA, left atrium; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

https://doi.org/10.1371/journal.pone.0196709.t001

Lipid species were identified by the accurate mass, isotope patterns, MS/MS fragmentation data, and relative retention time of the same species.

Multivariate pattern recognition methods were applied to identify lipidomic changes in patients with AF. Principle component analysis (PCA) score plots showed better separation in the negative ion mode between patients and healthy controls than in the positive ion mode (Fig 1A and 1B). The reproducibility of metabolite signals was confirmed by quality control samples injected repeatedly between samples in the PCA score plots. According to partial least squares discriminant analysis (PLS-DA), the two groups were clearly separated in both polarity modes (positive ion mode: R2X = 0.387, R2Y = 0.967, Q2 = 0.863; negative ion mode: R2X = 0.477, R2Y = 0.934, Q2 = 0.846) (Fig 1C and 1D).

Lipid metabolites with VIP scores > 1 in the PLS-DA and a p value < 0.05 were considered significant lipid species; a total of 33 lipids were identified (Table 2). The levels of all identified FFAs were lower in AF patients than in the controls. LysoPC, LysoPE, and PC levels were greater in AF patients than in controls when they had a relatively low degree of unsaturation; by contrast, these species were decreased in AF patients when they had a relatively high degree of unsaturation. Regarding the other lipid classes (i.e., PE, SM, TG, PA, and PI), only one lipid per class was significantly upregulated in AF patients relative to controls.

### Altered FFAs in AF patients

Although all FFAs examined were downregulated in AF patients relative to controls, other lipid species showed opposite patterns according to the degree of unsaturation. Therefore, all
detectable FFAs in plasma samples were examined. The intensities and compositions of the 18 FFAs are presented in Table 3. While the intensities of C14:0 and C16:0 saturated fatty acids (SFAs) were significantly lower in AF patients, the intensities of longer SFAs, such as C18:0, C20:0, and C22:0, were significantly higher in AF patients. The levels of all monounsaturated FFAs (MUFAs) and polyunsaturated FFAs (PUFAs) were significantly lower in AF patients. The FFA composition (% of total FFAs) indicated a higher percentage of SFAs (43.7% ± 6.2% vs. 32.9% ± 3.1%, \( p < 0.001 \)) and a lower percentage of MUFAs (33.7% ± 4.4% vs. 36.7% ± 2.6%, \( p = 0.003 \)) and PUFAs (22.6% ± 3.9% vs. 30.5% ± 3.3%, \( p < 0.001 \)) in AF patients than in controls.

Fig 1. Principle component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) score plots derived from the ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry spectra of plasma samples from healthy controls and patients with AF. PCA score plots in positive (A; \( R^2_X = 0.680, Q^2 = 0.456 \)) and negative (B; \( R^2_X = 0.699, Q^2 = 0.521 \)) ion mode, and PLS-DA score plots in positive (C; \( R^2_X = 0.387, R^2_Y = 0.967, Q^2 = 0.863 \)) and negative (D; \( R^2_X = 0.477, R^2_Y = 0.934, Q^2 = 0.846 \)) ion mode. Each ellipse was given by Hotelling’s T2 (0.95).

https://doi.org/10.1371/journal.pone.0196709.g001
To investigate the metabolic differences based on the recurrence of AF, the analyses described above were repeated on age-, sex-, and BMI-matched AF patients who experienced AF recurrence within 1 month after DCCV (recurrent AF group, n = 57) versus those who maintained sinus rhythm (non-recurrent AF group, n = 57). All baseline clinical characteristics were similar between the two groups (S1 Table).

Table 2. Lipids responsible for the differences between healthy controls and patients with AF.

| Class  | Identification | Healthy controls (n = 34) | AF patients (n = 34) | VIP value | Fold change (AF/Con) | P value |
|--------|----------------|--------------------------|---------------------|-----------|----------------------|---------|
| SFA    | FA 14:0        | 360 ± 91.1               | 216 ± 47.5          | 1.32      | 0.601                | <0.001  |
|        | FA 16:0        | 4780 ± 515               | 3550 ± 452          | 1.38      | 0.743                | <0.001  |
| MUFA   | FA 16:1        | 1180 ± 367               | 621 ± 372           | 1.10      | 0.528                | <0.001  |
|        | FA 18:1        | 6890 ± 807               | 4240 ± 1160         | 1.39      | 0.616                | <0.001  |
| PUFA   | FA 16:2        | 23.9 ± 7.61              | 9.37 ± 4.05         | 1.34      | 0.393                | <0.001  |
|        | FA 18:2        | 4650 ± 636               | 2320 ± 815          | 1.51      | 0.498                | <0.001  |
|        | FA 18:3        | 826 ± 311                | 328 ± 174           | 1.27      | 0.398                | <0.001  |
|        | FA 20:2        | 89.8 ± 21.7              | 47.4 ± 12.9         | 1.33      | 0.527                | <0.001  |
|        | FA 20:3        | 117 ± 44.9               | 49.3 ± 14.1         | 1.26      | 0.420                | <0.001  |
|        | FA 20:4        | 246 ± 109                | 132 ± 37.4          | 1.00      | 0.539                | <0.001  |
|        | FA 22:4        | 48.0 ± 18.0              | 21.9 ± 6.43         | 1.21      | 0.455                | <0.001  |
|        | FA 22:5        | 198 ± 102                | 74.3 ± 32.0         | 1.10      | 0.376                | <0.001  |
| LysoPC | LysoPC 14:0    | 19.4 ± 4.29              | 26.7 ± 7.07         | 1.79      | 1.376                | <0.001  |
|        | LysoPC 16:0    | 1720 ± 264               | 2210 ± 349          | 2.09      | 1.286                | <0.001  |
|        | LysoPC 18:0    | 753 ± 157                | 893 ± 193           | 1.24      | 1.186                | 0.003   |
|        | LysoPC 18:1    | 331 ± 70.7               | 403 ± 103           | 1.29      | 1.218                | 0.005   |
|        | LysoPC 20:1    | 6.78 ± 1.86              | 8.09 ±1.79          | 1.19      | 1.193                | 0.003   |
|        | LysoPC 20:2    | 52.3 ± 23.9              | 38.3 ± 9.63         | 1.33      | 0.731                | 0.003   |
|        | LysoPC 22:4    | 2.76 ± 1.34              | 1.85 ± 0.597        | 1.45      | 0.670                | 0.001   |
|        | LysoPC 22:5    | 15.0 ± 9.36              | 11.2 ± 3.58         | 1.02      | 0.749                | 0.013   |
|        | LysoPC 22:6    | 105 ± 77.2               | 71.1 ± 23.6         | 1.13      | 0.658                | <0.001  |
| PC     | PC 30:0        | 109 ± 44.6               | 137 ± 48.9          | 1.12      | 1.249                | 0.007   |
|        | PC 32:0        | 562 ± 112                | 653 ± 114           | 1.30      | 1.162                | <0.001  |
|        | PC 38:3        | 1000 ± 291               | 848 ± 186           | 1.19      | 0.845                | 0.044   |
|        | PC 40:7        | 22.4 ± 5.87              | 19.8 ± 4.11         | 1.13      | 0.885                | 0.048   |
| LysoPE | LysoPE 16:0    | 9.74 ± 2.03              | 13.0 ± 2.93         | 1.82      | 1.337                | <0.001  |
|        | LysoPE 18:0    | 14.0 ± 2.05              | 17.4 ± 3.02         | 1.81      | 1.238                | <0.001  |
|        | LysoPE 20:4    | 18.2 ± 4.60              | 15.1 ± 4.02         | 1.23      | 0.834                | <0.001  |
|        | LysoPE 22:6    | 30.2 ± 11.1              | 23.3 ± 12.8         | 1.12      | 0.772                | <0.001  |
| PE     | PE 36:4        | 1.88 ± 0.407             | 2.21 ± 0.529        | 1.11      | 1.173                | 0.016   |
| SM     | SM d34:2       | 442 ± 79.6               | 506 ± 89.0          | 1.21      | 1.146                | 0.002   |
| PA     | PA 34:2        | 4.08 ± 0.909             | 5.48 ± 1.20         | 1.04      | 1.341                | <0.001  |
| PI     | PI 36:1        | 10.5 ± 3.24              | 16.6 ± 6.81         | 1.08      | 1.582                | <0.001  |
|        | PI 38:5        | 6.77 ± 2.40              | 8.60 ± 2.94         | 1.09      | 1.269                | 0.005   |

Data are presented as means ± standard deviations. Intensity was divided by 10^4. P values were calculated using the Mann–Whitney U test, with significance set at \( p < 0.05 \). Abbreviations: AF, atrial fibrillation; VIP, variable importance in the projection; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; LysoPC, lysophosphatidylcholine; PC, phosphatidylcholine; LysoPE, lysophosphatidylethanolamine; PE, phosphatidylethanolamine; SM, sphingomyelin; PA, phosphatidic acid; PI, phosphatidylinositol.

https://doi.org/10.1371/journal.pone.0196709.t002

Predicting the recurrence of AF after DCCV

To investigate the metabolic differences based on the recurrence of AF, the analyses described above were repeated on age-, sex-, and BMI-matched AF patients who experienced AF recurrence within 1 month after DCCV (recurrent AF group, n = 57) versus those who maintained sinus rhythm (non-recurrent AF group, n = 57). All baseline clinical characteristics were similar between the two groups (S1 Table).
Table 3. Intensities and compositions of free fatty acids (% of total free fatty acids) in plasma samples obtained from healthy controls and AF patients.

| FFA   | FFA intensity | FFA composition |
|-------|---------------|-----------------|
|       | Con (n = 35)  | AF (n = 35) | P value | Con (n = 35) | AF (n = 35) | P value |
| C14:0 | 360 ± 91.1    | 216 ± 47.5     | <0.001   | 1.61 ± 0.380 | 1.52 ± 0.244 | 0.397   |
| C16:0 | 4780 ± 515    | 3550 ± 452     | <0.001   | 21.5 ± 1.84  | 25.1 ± 2.51  | <0.001  |
| C18:0 | 2120 ± 275    | 2340 ± 341     | 0.004    | 9.63 ± 1.67  | 16.8 ± 3.83  | <0.001  |
| C20:0 | 14.7 ± 4.02   | 20.4 ± 7.16    | <0.001   | 0.0671 ± 0.0216 | 0.149 ± 0.0653 | <0.001  |
| C22:0 | 11.7 ± 3.11   | 14.1 ± 2.54    | <0.001   | 0.0534 ± 0.0179 | 0.103 ± 0.0292 | <0.001  |
| C16:1 | 1180 ± 367    | 621 ± 372      | <0.001   | 5.22 ± 1.35  | 4.11 ± 1.75  | 0.002   |
| C18:1 | 6890 ± 807    | 4240 ± 1160    | <0.001   | 30.9 ± 1.94  | 29.1 ± 3.00  | 0.007   |
| C20:1 | 120 ± 61.0    | 68.7 ± 27.9    | <0.001   | 0.536 ± 0.262 | 0.471 ± 0.155 | 0.326   |
| C16:2 | 23.9 ± 7.61   | 9.37 ± 4.05    | <0.001   | 0.106 ± 0.0274 | 0.0634 ± 0.0179 | <0.001  |
| C18:2 | 4650 ± 636    | 2320 ± 815     | <0.001   | 20.9 ± 2.09  | 15.8 ± 3.24  | <0.001  |
| C18:3 | 826 ± 311     | 328 ± 174      | <0.001   | 3.68 ± 1.26  | 2.28 ± 1.25  | <0.001  |
| C18:4 | 26.1 ± 22.6   | 8.56 ± 4.01    | <0.001   | 0.116 ± 0.0982 | 0.0601 ± 0.0281 | <0.001  |
| C20:2 | 89.8 ± 21.7   | 47.4 ± 12.9    | <0.001   | 0.399 ± 0.0713 | 0.326 ± 0.0481 | <0.001  |
| C20:3 | 117 ± 44.9    | 49.3 ± 14.1    | <0.001   | 0.517 ± 0.164 | 0.341 ± 0.0520 | <0.001  |
| C20:4 | 246 ± 109     | 132 ± 37.4     | <0.001   | 1.08 ± 0.376  | 0.928 ± 0.216 | 0.027   |
| C22:4 | 48.0 ± 18.0   | 21.9 ± 6.43    | <0.001   | 0.212 ± 0.0657 | 0.151 ± 0.0224 | <0.001  |
| C22:5 | 198 ± 102     | 74.3 ± 32.0    | <0.001   | 0.867 ± 0.378  | 0.506 ± 0.148 | <0.001  |
| C22:6 | 602 ± 412     | 307 ± 127      | <0.001   | 2.64 ± 1.56  | 2.132 ± 0.827 | 0.198   |
| SFA   | 7290 ± 689    | 6140 ± 637     | <0.001   | 32.9 ± 3.12  | 43.7 ± 6.19  | <0.001  |
| MUFA  | 8190 ± 1080   | 4930 ± 1500    | <0.001   | 36.7 ± 2.58  | 33.7 ± 4.38  | 0.003   |
| PUFA  | 6830 ± 1200   | 3290 ± 1070    | <0.001   | 30.5 ± 3.28  | 22.6 ± 3.90  | <0.001  |

Data are presented as means ± standard deviations. Intensity was divided by 10⁶. P values were calculated using the Mann–Whitney U test. Abbreviations: AF, atrial fibrillation; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid.

https://doi.org/10.1371/journal.pone.0196709.t003

Multivariate analyses on lipidomics did not indicate a definite separation according to AF recurrence (S2 Fig). The intensities and compositions of 18 FFAs were also identified, and the intensities of FA 16:2, 18:3, 18:4, and C22:5 were significantly lower in the recurrent AF group (S2 Table). Although the intensities of other FFAs were not significantly different between recurrent and non-recurrent AF patients, the pattern of changes was similar to that between the AF and control groups (Fig 2). A comparison of FFA composition (SFA, MUFA, and PUFA) also revealed a similar pattern of change (increased SFAs, and decreased MUFAs and PUFAs in recurrent AF patients), although the differences were not statistically significant (Fig 3).

Relative mRNA levels of inflammatory cytokines

Relative mRNA expression levels of inflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α were measured to confirm the inflammation condition in plasma samples of patients with AF. The expression in IL-1β and TNF-α were significantly increased in AF patients (Fig 4).

Discussion

Lipids have a wide range of biological functions, including energy storage, membrane structure, and cell signaling, with various lipid compositions and distributions [22, 23]. Changes in lipid metabolism are closely related to disease states, and thus a comprehensive lipid analysis
in biological systems can provide a better understanding of the pathogenesis of diseases and disease biomarkers for the diagnosis and prognosis of diseases, pharmaceutical discovery, and therapeutic effects [22].

We performed global lipid profiling to understand the lipid changes in AF patients. In PCA score plots, AF patients were clearly distinguished from healthy controls, and certain lipid metabolites that were altered in AF patients (i.e., FFAs, LysoPC, LysoPE, and PC) were confirmed to be responsible for this separation. In particular, we found that a characteristic change depends on the degree of unsaturation of fatty acids in the specific lipid classes, including FFAs and phospholipids. To better understand this association, we investigated all FFAs in plasma samples. In total, 18 FFAs detected in AF patients exhibited distinct differences, depending on the degree of unsaturation: SFAs were upregulated, and MUFAs and PUFAs were downregulated in AF patients relative to controls.

Fig 2. Intensities of free fatty acids in plasma samples obtained from healthy controls and AF patients and (A) and non-recurrent and recurrent AF patients (B). P values were calculated using the Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.

https://doi.org/10.1371/journal.pone.0196709.g002

Fig 3. Compositions of SFAs, MUFAs, and PUFAs (% of total free fatty acids) in plasma samples obtained from healthy controls and AF patients (A) and non-recurrent and recurrent AF patients (B). Data are presented as means ± standard deviations. P values were calculated using the Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.

https://doi.org/10.1371/journal.pone.0196709.g003
Although electrical cardioversion is usually successful in restoring sinus rhythm in patients with AF [4], maintaining sinus rhythm after successful cardioversion is often difficult. Old age, a large LA, the presence of other cardiac problems, and a longer duration of AF are correlated with AF recurrence [23, 24]. We investigated whether metabolic changes can predict AF recurrence after successful DCCV. For this purpose, we compared the lipidomic profiles between recurrent and non-recurrent AF patients, after matching to adjust for other potential risk factors of AF recurrence. Although 12-lead ECG has limited power to detect paroxysmal AF, most of AF recurred after cardioversion were persistent type which 12-lead ECG could detect. The lipidomic differences between the recurrent and non-recurrent AF patients were not significant, nevertheless the intensities of FFAs showed a similar pattern to those from the comparison between AF and the control group: the SFA level in plasma was higher in the recurrent AF group, while the levels of MUFAs and PUFAs were lower in the recurrent AF group. As patients with progressed AF are more likely to experience AF recurrence after rhythm treatment [25], these results support the lipidomic differences in AF patients compared to healthy controls.

Although FFAs are a small proportion of the total fatty acids in plasma, they serve many important functions in the body [26]. FFAs released from adipose tissue by lipolysis are an important energy source and are tightly regulated in accordance with the energy needs of the body [27, 28]. FFA oxidation requires more oxygen than glycolysis, and elevated FFAs are related to cardiovascular diseases [27]. In particular, excess FFAs lead to plasma membrane damage and contribute to myocardial dysfunction and ventricular fibrillation [27, 28]. In a large prospective cohort study, the plasma concentration of total FFAs was shown to predict the future risk of AF occurrence [29]. However, not all FFAs act similarly in cardiovascular diseases: they are believed to function differently depending on their chemical structure [30–32]. Because chain length and saturation can affect the permeability, rigidity, and fluidity of the phospholipid membrane, changes in the degree of unsaturation or chain length may cause different responses for oxidative damage by reactive oxygen species [30]. The increased levels of SFAs in the AF patients may have been influenced by adipose-stimulated lipolysis [32] and thus contributed to inflammation [31]. Conversely, the decrease in PUFAs may have resulted from their degradation from reactive oxygen species [32]. PUFAs also exhibit anti-inflammatory
effects by downregulating the release of pro-inflammatory cytokines [31, 33]. Moreover, the present data are consistent with a previous study in which SFAs and PUFAs were shown to play different pro- and anti-inflammatory roles with regard to inflammation [31]. This study demonstrated that FFAs, including SFAs, MUFAs, and PUFAs, are elevated or reduced in plasma samples of AF patients, supporting an important role for inflammation in the pathogenesis of AF.

Several studies have reported an association between inflammation and AF and shown elevated levels of inflammatory markers or mediators, such as C-reactive protein (CRP), TNF-α, IL-2, IL-6, and IL-8 in patients with AF [12, 34–37]. It is known that PUFAs might regulate the expression of genes related to promoting inflammation [38]. Actually, PUFA supplementation reduced mRNA levels for inflammatory cytokines including IL-1β and TNF-α in the mononuclear cells isolated from human whole blood [39], human gastric tissues [40], bovine chondrocytes [41]. Furthermore, emerging evidence suggests that inflammation plays a major role in the initiation and perpetuation of AF. In this study, CRP levels were not routinely measured in the enrolled patients. Instead, relative mRNA expression levels of inflammatory cytokines, such as IL-1β and TNF-α, which revealed that the expression of IL-1β and TNF-α was significantly upregulated in AF patients relative to controls. However, recent clinical trials reported little evidence of benefit of supplementation on incident or recurrent AF [42], therefore, further studies on the correlation between cytokines expression and lipid levels would be helpful to evaluate the association between inflammatory cytokine mRNA and lipid species. We suggest that reduced PUFAs may affect inflammatory cytokine production and the elevated expression of cytokines could be associated with the initiation and/or perpetuation of AF.

In conclusion, AF patients showed discernible lipid profiles compared to healthy controls: levels of SFA were elevated, while PUFA levels were decreased in plasma from AF patients. These changes may be associated with enhanced inflammation and pro-arrhythmic conditions, supporting the association between FFA levels and the risk of AF development and progression.

Supporting information

S1 Table. Clinical characteristics for non-recurred and recurred AF patients.

(DOCX)

S2 Table. Intensities and compositions of free fatty acids (% of total free fatty acids) in plasma samples in non-recurred and recurred AF patients.

(DOCX)

S1 Fig. Total ion chromatogram of plasma extracts obtained from QC sample. (A) Positive ion mode and (B) negative ion mode.

(TIF)

S2 Fig. PCA score plots derived from the ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS) spectra of plasma from non-recurred and recurred AF patients. PCA score plots in positive (A; R2X = 0.708, Q2 = 0.526) and negative ion mode (B; R2X = 0.705, Q2 = 0.509). Each ellipse was given by Hotelling’s T2 (0.95).

(TIF)

Author Contributions

Conceptualization: Youngae Jung, Youngjin Cho, Eue-Keun Choi, Geum-Sook Hwang.
Data curation: Youngae Jung, Youngjin Cho, Nami Kim, Il-Young Oh, Sang Won Kang, Eue-Keun Choi, Geum-Sook Hwang.

Formal analysis: Youngjin Cho, Nami Kim, Il-Young Oh, Sang Won Kang, Eue-Keun Choi, Geum-Sook Hwang.

Funding acquisition: Eue-Keun Choi, Geum-Sook Hwang.

Investigation: Youngae Jung, Youngjin Cho, Nami Kim, Il-Young Oh.

Methodology: Youngae Jung, Youngjin Cho, Nami Kim, Il-Young Oh.

Project administration: Youngae Jung, Eue-Keun Choi, Geum-Sook Hwang.

Resources: Youngae Jung, Youngjin Cho, Nami Kim, Il-Young Oh, Sang Won Kang, Eue-Keun Choi, Geum-Sook Hwang.

Supervision: Eue-Keun Choi, Geum-Sook Hwang.

Writing – original draft: Youngae Jung, Youngjin Cho.

Writing – review & editing: Youngae Jung, Youngjin Cho, Nami Kim, Il-Young Oh, Sang Won Kang, Eue-Keun Choi, Geum-Sook Hwang.

References

1. Okada A, Kashima Y, Tomita T, Takeuchi T, Aizawa K, Takahashi M, et al. Characterization of cardiac oxidative stress levels in patients with atrial fibrillation. Heart Vessels 2016; 31:80–7. https://doi.org/10.1007/s00380-014-0582-8 PMID: 25260402

2. Köröglu S, Tuncer C, Acar G, Akçay A, Sökmen G, Yalçıntaş S, et al. Relation of inflammatory and oxidative markers to the occurrence and recurrence of persistent atrial fibrillation. Arch Turk Soc Cardiol 2012; 40:499–504.

3. Kim SM, Kim JM, Shin DG, Kim JR, Cho KH. Relation of atrial fibrillation (AF) and change of lipoproteins: Male patients with AF exhibited severe pro-inflammatory and pro-atherogenic properties in lipoproteins. Clin Biochem 2014; 47:869–75. https://doi.org/10.1016/j.clinbiochem.2013.10.026 PMID: 24201066

4. Sterling M, Huang DT, Ghoraani B. Developing time-frequency features for prediction of the recurrence of atrial fibrillation after electrical cardioversion therapy. Conf Proc IEEE Eng Med Biol Soc 2014; 2014:5498–501. https://doi.org/10.1109/EMBC.2014.6944871 PMID: 25571239

5. Zografos T, Maniotis C, Katsivas A, Katritsis D. Relationship between brain natriuretic peptides ad recurrence of atrial fibrillation after successful direct current cardioversion: A meta-analysis. Pacing Clin Electrophysiol 2014; 37:1530–7. https://doi.org/10.1111/pace.12477 PMID: 25113607

6. Tielerman RG, Van Gelder IC, Crijsns HJGM, De Kam PJ, Van Den Berg MP, Haaksma J, et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31:167–73. PMID: 9426036

7. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369–429. https://doi.org/10.1093/eurheartj/ehq278 PMID: 20802247

8. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicoz PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193–7. PMID: 2909999

9. Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989; 63:1065–8. PMID: 2705378

10. Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinnaum D, Jones DP, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007; 53:1652–7. https://doi.org/10.1373/clinchem.2006.083923 PMID: 17599998

11. Cao H, Wu Y, Li Q, Wu Y, Zhou Q, Rae OD, et al. Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation. Int J Cardiol 2014; 170:287–302.
12. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60:2263–70. https://doi.org/10.1016/j.jacc.2012.04.063 PMID: 23194937

13. Nam M, Choi MS, Jung S, Jung Y, Choi JY, Ryu DH, et al. Lipidomic profiling of liver tissue from obesity-prone and obesity-resistant mice fed a high fat diet. Sci Rep 2015; 5:16984. https://doi.org/10.1038/srep16984 PMID: 26592433

14. Park JY, Lee SH, Shin MJ, Hwang GS. Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One 2015; 10:e0135228. https://doi.org/10.1371/journal.pone.0135228 PMID: 26258408

15. Kim KE, Jung Y, Min S, Nam M, Heo RW, Jeon BT, et al. Caloric restriction of db/db mice reverts hepatic steatosis and body weight with divergent hepatic metabolism. Sci Rep 2016; 6:30111. https://doi.org/10.1038/srep30111 PMID: 27439777

16. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, et al. Combined metabolomics and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008; 51:585–94. https://doi.org/10.1016/j.jacc.2007.09.055 PMID: 18237690

17. De Souza AI, Cardin S, Wail R, Chung YL, Vijaykumar M, Maguy A, et al. Proteomic and metabolic analysis of atrial proﬁbrillatory remodeling in congestive heart failure. J Mol Cell Cardio 2010; 49:851–63.

18. Alonso A, Yu B, Qureshi WT, Grams ME, Selvin E, Soliman EZ, et al. Metabolomics and incidence of atrial fibrillation in African Americans: The atherosclerosis risk in communities (ARIC) study. PLoS One 2015; 10:e0142610. https://doi.org/10.1371/journal.pone.0142610 PMID: 26544570

19. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. As association between lipid profile and risk of atrial fibrillation. Circ J 2011; 75:2767–74. PMID: 21914959

20. Norby FL, Eryd SA, Niemeijer MN, Rose LM, Smith AV, Yin X, et al. Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFlagen Consortium. PLoS One. 2016; 11: e0151932. https://doi.org/10.1371/journal.pone.0151932 PMID: 26999784

21. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071–104. https://doi.org/10.1161/CIR.000000000000040 PMID: 24682348

22. Zhao YY, Miao H, Cheng XL, Wei F. Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. Chem Biol Interact 2015; 240:220–38. https://doi.org/10.1016/j.cbi.2015.09.005 PMID: 26358168

23. Orešić M, Hänninen VA, Vidal-Puig A. Lipidomics: a new window to biomedical frontiers. Trends Biotechnol 2008; 26:647–52. https://doi.org/10.1016/j.tibtech.2008.09.001 PMID: 18951641

24. Wei W, Ge JB, Zou Y, Lin L, Cai Y, Liu XB, et al. Anatomical characteristics of pulmonary veins for the prediction of postoperative recurrence after radiofrequency catheter ablation of atrial fibrillation. PLoS One 2014; 9:e93817. https://doi.org/10.1371/journal.pone.0093817 PMID: 24705909

25. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849–54. https://doi.org/10.1056/NEJM199906173402401 PMID: 10369847

26. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010; 51:3299–305. https://doi.org/10.1194/jlr.M009449 PMID: 20671299

27. Pilz S, März W. Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med 2008; 46:429–34. https://doi.org/10.1015/CCLM.2008.118 PMID: 18605928

28. Oliver MF. Sudden cardiac death: the lost fatty acid hypothesis. Q J Med 2006; 99:701–9.

29. Khawaja O, Bartz TM, Ix JH, Heckbert SR, Kizer JR, Ziemann SJ, et al. Plasma free fatty acids and risk of atrial fibrillation (from the Cardiovascular Health Study). Am J Cardiol 2012; 110:212–6. https://doi.org/10.1016/j.amjcard.2012.03.010 PMID: 22503582

30. Assies J, Mocking RJT, Lok A, Ruhe HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand 2014; 130:163–80. https://doi.org/10.1111/acps.12265 PMID: 24649967

31. Volpe CM, Nogueira-Machado JA. The dual role of free fatty acid signaling in inflammation and therapeutics. Recent Pat Endocr Metab Immune Drug Discov 2013; 7:189–97. PMID: 23909843

32. Rivai T, Clig-Frais C, Silva-Sifontes S, Garcia J, Riu B, Salvayre R, et al. Alteration of plasma phospholipid fatty acid profile in patients with septic shock. Biochimie 2013; 95:2177–81. https://doi.org/10.1016/j.biochi.2013.09.005 PMID: 23954620

33. Kumar KV, Rao SM, Gayani R, Mohan IK, Naidu MUR. Oxidant stress and essential fatty acids in patients with risk and established ARDS. Clin Chim Acta 2000; 298:111–20. PMID: 10876008
34. Hadi HAR, Alsheikh-Ali AA, Mahmeed WAL, Al Suwaidi JM. Inflammatory cytokines and atrial fibrillation: current and prospective views. J Inflamm Res 2010; 3:75–97. https://doi.org/10.2147/JIR.S10095 PMID: 22096359
35. Tang RB, Dong JZ, Liu XP, Ma CS. Inflammation and atrial fibrillation: Is Chlamudia pneumoniae a candidate pathogen of atrial fibrillation? Med Hypotheses 2006; 67:462–6. https://doi.org/10.1016/j.mehy.2006.03.017 PMID: 16793213
36. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015; 12:230–43. https://doi.org/10.1038/nrcardio.2015.2 PMID: 25622848
37. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein M, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7:438–44. https://doi.org/10.1016/j.hrthm.2009.12.009 PMID: 20153266
38. Allam-Ndoul B, Guénard F, Barbier O, Vohl M. Effects of n-3 fatty acids on the expression of inflammation genes in THP-1 macrophages. Lipids Health Dis 2016; 15:69–75. https://doi.org/10.1186/s12944-016-0241-4 PMID: 27044314
39. Weaver KL, Ivester P, Seeds M, Case LD, Arm JP, Chilton FH. Effect of dietary fatty acids on inflammatory gene expression in Healthy Humans. J Bio Chem 2009; 284:15400–7.
40. Hosseinzadeh A, Ardebili SM. Efficacy of omega fatty acid supplementation on mRNA expression level of tumor necrosis factor alpha in patients with gastric adenocarcinoma. J Gastrointest Cancer 2016; 47:287–93. https://doi.org/10.1007/s12029-016-9826-4 PMID: 27170003
41. Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B. N-3 Fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Bio Chem 2000; 275:721–4.
42. Siscovick DS, Barringer TA, Fretts AM, Wu JHY, Lichtenstein AH, Costello RB, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: A science advisory from the American Heart Association. Circulation 2017; 135:e867–e884. https://doi.org/10.1161/CIR.0000000000000482 PMID: 28289069